Novel Agents in the Treatment of Lung Cancer:
Advances in EGFR Inhibitors
Sixth Cambridge Conference - October 2008
This program was based on a conference of multidisciplinary of leaders in lung cancer research and clinical care. The program developed content for two CME activities for oncologists and other medical professionals who assess, treat and counsel patients with lung cancer.
The program was directed by Thomas J. Lynch, Jr, MD, Chief, Hematology/Oncology, Massachusetts General Hospital Cancer Center.
Links to the online activity and a printable PDF are located below.
The activity is no longer active.
Statement of Need
Agents targeting the epidermal growth factor receptor (EGFR) have shown dramatic efficacy in a subset of patients with non–small cell lung cancer and have been shown in some circumstances to improve outcomes for larger groups of patients. It is now recognized, however, that patients whose cancer initially responds to these inhibitors eventually acquire resistance to such therapy. Recent research provides important insights for patient treatment. Oncologists who assess, treat, and counsel lung cancer patients need to be aware of important new data on EGFR inhibitor response and resistance, new EGFR inhibitors in development, and current recommendations for lung cancer treatment.
Educational Grant Support
Supported by educational grants provided by Genentech, Bristol-Myers Squibb and ImClone Systems, Inc., and Pfizer, Inc.
Sponsorship
CME sponsorship was provided by InforMEDical Communications, Inc.
